dal-GenE

STUDY IDENTIFIER:

dal-GenE

CONDITION:

Acute Coronary Syndrome

CONTACT INFO:

Christine Majeski   |   Christine.Majeski@allina.com   |   612-863-3546

DESCRIPTION:

Evaluate the Effects of DalcetrapibDalcetrapib is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012 on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)Acute Coronary Syndrome.

CRITERIA LIST/ QUALIFICATIONS:

  • Subjects recently hospitalized for ACS (between 4 and 12 weeks following the index event).
  • AA genotype at variant gene as determined by Genotype Assay testing.
  • Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization.

INVESTIGATORS:

Thomas Knickelbine, MD

SPONSORS:

DalCor Pharmaceuticals

STATUS:

Open/Enrolling